Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas.

The p53 protein is accumulated in tumor cells of many human cancers and can elicit in vivo humoral and proliferative responses. Rare reports about p53-mediated tumor recognition by CTLs have remained questioned. We therefore studied a panel of breast tumor and melanoma cell lines that we assayed for the presence of accumulated p53 and surface HLA-A2 and for the presentation of p53 epitopes. From PBMC of a healthy donor, we have generated a CTL line, D5/L9V, directed against HLA-A2-restricted peptide 264-272 from wild-type p53. It efficiently lysed breast adenocarcinomas MCF-7, MCF7/RA1, and MDA-MB-231, and melanoma M8, which all accumulate the p53 protein. Using competition assays, we made sure that tumor lysis by D5/L9V was due to recognition of endogenously produced p53 peptide 264-272 associated with the HLA-A2.1 molecule on the surface of these tumor cells. Cells with undetectable levels of wild-type p53, such as lymphoblastoid cells and melanoma M74, were not recognized by D5/L9V. Neither were breast tumor cell line MCF7/ADR nor melanoma line M44 because of HLA loss. This study therefore shows that it is possible to obtain in vitro CTL lines that specifically recognize a p53 epitope spontaneously presented by a variety of HLA-A2+ transformed cell lines provided they display abnormal patterns of p53 expression. This work points out that breast tumors and melanomas share a p53 epitope, and raises hopes for future immunotherapeutic approaches.

[1]  M. Theobald,et al.  Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes , 1997, The Journal of experimental medicine.

[2]  L. Fugger,et al.  Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Guillet,et al.  A wild‐type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells , 1996, European journal of immunology.

[4]  M. Cheever,et al.  Oncogenic proteins as tumor antigens. , 1996, Current opinion in immunology.

[5]  B. Iacopetta,et al.  Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. , 1996, Human pathology.

[6]  P. Robbins,et al.  Human tumor antigens recognized by T cells. , 1996, Current opinion in immunology.

[7]  T. Soussi.  The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy. , 1996, Immunology today.

[8]  I. Auger,et al.  Molecular mimicry reflected through database screening: serendipity or survival strategy? , 1996, Immunology today.

[9]  H. Stauss,et al.  A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein. , 1996, Journal of immunology.

[10]  G. Opdenakker,et al.  Introduction of the interferon γ gene into mouse T lymphoma cells with low MHC class I-expression results in selective induction of H-2Dk and concomitant enhanced metastasis , 1996, Cancer Immunology, Immunotherapy.

[11]  H. Sakamoto,et al.  Therapy of murine tumors with p53 wild-type and mutant sequence peptide- based vaccines , 1996, The Journal of experimental medicine.

[12]  P. Bruggen,et al.  Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.

[13]  A. Levine,et al.  Targeting p53 as a general tumor antigen. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[14]  T. Eberlein,et al.  Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. , 1995, Journal of immunology.

[15]  S. Rosenberg,et al.  Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. , 1995, Cancer research.

[16]  M. Claesson,et al.  T Cell‐Mediated Cytotoxicity Against p53‐Protein Derived Peptides in Bulk and Limiting Dilution Cultures of Healthy Donors , 1995, Scandinavian journal of immunology.

[17]  M. Mathieu,et al.  Primary proliferative T cell response to wild‐type p53 protein in patients with breast cancer , 1995, European journal of immunology.

[18]  E. Balcer-Kubiczek,et al.  p53 mutational status and survival of human breast cancer MCF-7 cell variants after exposure to X rays or fission neutrons. , 1995, Radiation research.

[19]  S. Gnjatic,et al.  Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules , 1995, European journal of immunology.

[20]  F. Chisari,et al.  Induction in vitro of a primary human antiviral cytotoxic T cell response , 1995, European journal of immunology.

[21]  L. Old,et al.  A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[22]  X. Chen,et al.  A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. , 1993, Genes & development.

[23]  S. H. van der Burg,et al.  In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53 , 1993, European journal of immunology.

[24]  S. H. van der Burg,et al.  Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[25]  J. Berzofsky,et al.  A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. , 1993, Cancer research.

[26]  N. Lassam,et al.  Overexpression of p53 is a late event in the development of malignant melanoma. , 1993, Cancer research.

[27]  D. Pim,et al.  Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer , 1982, International journal of cancer.

[28]  Thierry Soussi,et al.  Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation , 1996, Nucleic Acids Res..

[29]  S. Rosenberg,et al.  T-cell recognition of self peptides as tumor rejection antigens , 1996, Immunologic research.

[30]  J. Selkirk,et al.  Multiple p53 protein isoforms and formation of oligomeric complexes with heat shock proteins Hsp70 and Hsp90 in the human mammary tumor, T47D, cell line. , 1994, Applied and theoretical electrophoresis : the official journal of the International Electrophoresis Society.

[31]  T. Soussi,et al.  Cancer and the heat shock response. , 1994, European journal of cancer.

[32]  Katsuo Suzuki,et al.  Protein synthesis—dependent cytoplasmic translocation of p53 protein after serum stimulation of growth‐arrested MCF‐7 cells , 1993, Molecular carcinogenesis.

[33]  Walter F. Bodmer,et al.  MHC antigens and cancer: implications for T-cell surveillance. , 1992 .